Impact of a Nurse for Migraine Management: the IMPACT Project (IMPACT)

December 6, 2016 updated by: Elizabeth Leroux, Notre-Dame Hospital, Montreal, Quebec, Canada

Impact of a Nursing Intervention on the Clinical Evolution of Patients at a University Migraine Clinic

Headache disorders are prevalent, disabling, under recognized, under diagnosed and under treated. Migraine has a prevalence of 10% in men and 25% in women in Canada. The treatment of migraine is based on patient education (lifestyle habit modification, trigger avoidance), and pharmacological acute treatment and prophylaxis. A multidisciplinary approach allows a repartition of tasks between different health professionals.

In a 2010 meeting, the Canadian Headache Society members supported the concept of Headache Centers, and a headache nurse was judged as an essential component of such centers.

Gaul has reviewed the structured multidisciplinary approach that could be used in a headache centre and the existing studies using such structures. Five studies did include a headache nurse. No study did observe the impact of a nurse only. Resources in medical care are limited. One study did use a program of 96 hours, which does not seem realistic on the long-term and for a large pool of patients in a public hospital. Patients are not always able to pay for paramedical help such as physiotherapy and psychotherapy. Even if they do, finding a specialized therapist for chronic headache is difficult. Defining the role of a nurse and demonstrating the impact on patient care is therefore a first step in the concept of a headache center. Possible roles of a headache nurse according to Gaul are patient education, follow-up of the treatment plan, addressing patient queries, and monitoring of patient progress. The headache nurse may also participate in research projects. In a hospital Headache Clinic, the nurse may be involved in intra-venous treatments and blood sampling for research.

In summary, evidence to demonstrate the impact of a nurse in a headache clinic is lacking. We propose to study this aspect prospectively. A study with positive findings would encourage health ministers to fund and support headache nurses for headache centers across Canada for headache management. Chronic headache and therefore chronic migraine would be a focus of such centers, since most patients seen in specialized centers are chronic.

HYPOTHESIS: The addition of a headache nurse to the headache team will help the CHUM Migraine Clinic to improve treatment outcome, and reduce the burden of headache. This multidisciplinary approach will also allow a higher efficiency of the team.

Study Overview

Detailed Description

STUDY DESIGN:

The goal of this study is to compare two treatment approaches for migraineurs. The first approach will be based on the physician only and is limited to fixed appointments (control group). The second approach will be based on a team involving a headache nurse (active group) who will participate in patient education and follow-up. The goal is to improve patient outcome but also physician productivity.

First 100 patients (control group, phase 1): patients with episodic and chronic migraine will be screened, sign consent and be enrolled. They will be seen by the physician only, without the nurse's support. This situation will reproduce the actual conditions at the clinic. During this phase, the nurse will be involved in the follow-up of known patients (who will not be included in the protocol) and data collection. She will develop her headache management abilities and help the physicians to develop some educational tools for patients.

Following 100 patients (active group, phase 2) : patients with episodic and chronic migraine will be screened and enroled. They will be seen by the physician and nurse team, with a treatment plan tailored to specific needs including regular scheduled visits, follow-up of chronification factors and educational sessions. Phone call follow-ups will be planned. Patients will have an easier and quicker contact with the team in an emergency situation.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montreal, Quebec, Canada, H2L 4M1
        • Hôpital Notre-Dame

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients followed at the migraine clinic at the Notre-Dame Hospital in Montreal

Description

INCLUSION CRITERIA:

  • Age 18 or more
  • Diagnosis of migraine, chronic or episodic, at the first visit. We expect the majority of patients to suffer form frequent or chronic migraine.
  • Consent to participate in the CHUM Migraine Clinic IMPACT project.
  • For future post-hoc analysis, groups will be stratified according to baseline headache frequency (all severity included), assessed retrospectively at the first visit:

    • <6 headache days per month,
    • 6 to 14 headache days per month
    • 15 or more headache days per month

EXCLUSION CRITERIA:

  • Patients whom first headache diagnosis is not migraine (for example post-traumatic headache, cluster headache, trigeminal neuralgia, facial pain).
  • Women with ongoing or planned pregnancy.
  • Patient with an active psychiatric condition (needing hospitalisation or psychosis).
  • Patient with mental retardation impairing assessment or follow-up.
  • Patient with an active medical condition which may lead to frequent hospitalisations (eg active cancer, organ graft, hemodialysis etc). This will be determined and detailed by the evaluating physician.
  • Active drug addiction or alcoholism.
  • Active follow-up at a pain clinic.
  • Patient speaking a language other than french and incapable to communicate in a reliable way.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Physician based approach
Patients will be managed as usual at the clinic without the intervention of the nurse.
Physician and nurse
Patients will be managed with the help of the nurse for education and follow-up.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hit-6 score change
Time Frame: Baseline and 8 months
HIT-6 score change between inclusion and 8 month.
Baseline and 8 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of moderate and severe headache days
Time Frame: Baseline and 8 months
Variation in the frequency of moderate or severe headache days per month between the first, fourth and eighth month after inclusion.
Baseline and 8 months
Frequency of headache days
Time Frame: Baseline and 8 months
Change in the frequency of headache days, all severity included, between the first month and the seventh and eight months following inclusion.
Baseline and 8 months
Chronic headache status
Time Frame: Baseline and 1 year
Percent of patients who were chronic (more than 3 months with >15 headache days per month, retrospective) at entry and were episodic at one year (according to calendars).
Baseline and 1 year
Medication overuse
Time Frame: Baseline and 8 months
Percent of patients with medication overuse at entry and were not overusing anymore at 8 months.
Baseline and 8 months
Acute medication intake
Time Frame: Baseline and 8 months
Change in the number of days per month with acute medication use between the first month after inclusion and the seventh and eight months following inclusion.
Baseline and 8 months
Efficacy of acute treatment
Time Frame: at 8 months
Percent of patients who succeeded in finding a successful and properly used acute treatment at month eight, according to four criteria: efficacy, reliability, absence of recurrence, absence of significant side effects.
at 8 months
Response rate to prophylactics
Time Frame: at 8 months
Percent of patients who did complete a successful (>50% response and no significant side-effects) preventive treatment trial at month eight after inclusion.
at 8 months
Short Form 12 score
Time Frame: Baseline and 8 months
Change in SF-12 scores between inclusion and third visit. SF-12 is a quality of life questionnaire.
Baseline and 8 months
Visits to the emergency department
Time Frame: over 1 year
Number of headache-related emergency department visits per patient during the year following their inclusion.
over 1 year
Severe adverse effects from treatments
Time Frame: over 1 year
Percent of patients with a severe adverse effect from a treatment (necessitating hospitalization, emergency visit or specific treatment).
over 1 year
Phone calls returned
Time Frame: per 1 month
Number of phone calls returned per month
per 1 month
Patient satisfaction
Time Frame: at 8 months
Satisfaction of patients, evaluated by a customized questionnaire.
at 8 months
Phone call return delay
Time Frame: for each phone call, mean
Mean delay for returning the call (number of week days between the date of the call and the date of the return).
for each phone call, mean
Global improvement
Time Frame: at 8 months
Evaluation of physician of the global improvement of the patient.
at 8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Elizabeth Leroux, M.D., FRCPC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2013

Primary Completion (Actual)

November 1, 2015

Study Completion (Actual)

November 1, 2015

Study Registration Dates

First Submitted

February 23, 2013

First Submitted That Met QC Criteria

March 2, 2013

First Posted (Estimate)

March 5, 2013

Study Record Updates

Last Update Posted (Estimate)

December 8, 2016

Last Update Submitted That Met QC Criteria

December 6, 2016

Last Verified

December 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Migraine

Subscribe